Evidence map›Paper›PMID 42032543›Full record

ArticleBMC cancer2026

Prognostic value of CALLY index in patients with locally advanced non-small cell lung cancer treated with thoracic radiotherapy.

Xiaoming Yin, Xinying He, Wei Guo, Hongling Lu, Haijun Chen, Rujing Huang, Tingting Hu, Li Xiao, Yunchuan Sun, Kui Fan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xiaoming YinDepartment of Radiation Oncology, Hebei Province Integrated Traditional Chinese and Western Medicine 3D Printing Technology Innovation Center, Hebei Province Cangzhou Hospital of Integrated Traditional and Western Medicine, Affiliated Hospital of Hebei Medical University, No. 31, Huanghe West Road, Yunhe District, Cangzhou, Hebei, 061000, China.
Xinying HeDepartment of Radiation Oncology, Hebei Province Integrated Traditional Chinese and Western Medicine 3D Printing Technology Innovation Center, Hebei Province Cangzhou Hospital of Integrated Traditional and Western Medicine, Affiliated Hospital of Hebei Medical University, No. 31, Huanghe West Road, Yunhe District, Cangzhou, Hebei, 061000, China.
Wei GuoDepartment of Radiation Oncology, Hebei Province Integrated Traditional Chinese and Western Medicine 3D Printing Technology Innovation Center, Hebei Province Cangzhou Hospital of Integrated Traditional and Western Medicine, Affiliated Hospital of Hebei Medical University, No. 31, Huanghe West Road, Yunhe District, Cangzhou, Hebei, 061000, China.
Hongling LuDepartment of Radiation Oncology, Hebei Province Integrated Traditional Chinese and Western Medicine 3D Printing Technology Innovation Center, Hebei Province Cangzhou Hospital of Integrated Traditional and Western Medicine, Affiliated Hospital of Hebei Medical University, No. 31, Huanghe West Road, Yunhe District, Cangzhou, Hebei, 061000, China.
Haijun ChenDepartment of Anesthesiology, Cangzhou Central Hospital, Cangzhou, Hebei, 061000, China.
Rujing HuangDepartment of Radiation Oncology, Hebei Province Integrated Traditional Chinese and Western Medicine 3D Printing Technology Innovation Center, Hebei Province Cangzhou Hospital of Integrated Traditional and Western Medicine, Affiliated Hospital of Hebei Medical University, No. 31, Huanghe West Road, Yunhe District, Cangzhou, Hebei, 061000, China.
Tingting HuDepartment of Radiation Oncology, Hebei Province Integrated Traditional Chinese and Western Medicine 3D Printing Technology Innovation Center, Hebei Province Cangzhou Hospital of Integrated Traditional and Western Medicine, Affiliated Hospital of Hebei Medical University, No. 31, Huanghe West Road, Yunhe District, Cangzhou, Hebei, 061000, China.
Li XiaoDepartment of Radiation Oncology, Hebei Province Integrated Traditional Chinese and Western Medicine 3D Printing Technology Innovation Center, Hebei Province Cangzhou Hospital of Integrated Traditional and Western Medicine, Affiliated Hospital of Hebei Medical University, No. 31, Huanghe West Road, Yunhe District, Cangzhou, Hebei, 061000, China.
Yunchuan SunDepartment of Radiation Oncology, Hebei Province Integrated Traditional Chinese and Western Medicine 3D Printing Technology Innovation Center, Hebei Province Cangzhou Hospital of Integrated Traditional and Western Medicine, Affiliated Hospital of Hebei Medical University, No. 31, Huanghe West Road, Yunhe District, Cangzhou, Hebei, 061000, China. 13932719095@163.com.
Kui FanDepartment of Radiation Oncology, Hebei Province Integrated Traditional Chinese and Western Medicine 3D Printing Technology Innovation Center, Hebei Province Cangzhou Hospital of Integrated Traditional and Western Medicine, Affiliated Hospital of Hebei Medical University, No. 31, Huanghe West Road, Yunhe District, Cangzhou, Hebei, 061000, China. fankui0308@163.com.

Funding

Scientific Research Foundation of Hebei Province Health Commission 20211577
6 · The paper itself

Abstract

backgroundAs a novel inflammatory-nutritional biomarker, the C-reactive protein–albumin–lymphocyte (CALLY) index has demonstrated significant prognostic value in several cancer types. However, its predictive significance for patients with locally advanced non-small cell lung cancer (LA-NSCLC) treated with thoracic radiotherapy (RT) remains elusive. This study aimed to investigate the relationship between the pre/post-treatment CALLY index and the prognosis of patients with LA-NSCLC treated with thoracic RT.

methodsIn this retrospective study, a cohort of 218 LA-NSCLC patients who underwent thoracic RT between 2012 and 2018 was assessed. The calculation of CALLY involved the use of C-reactive protein (CRP) level, albumin level, and lymphocyte count. Cox proportional hazards regression and the Kaplan-Meier survival analyses were employed to analyze the relationships between various variables and overall survival (OS), local progression-free survival (LPFS), and distant metastasis-free survival (DMFS).

resultsMultivariate Cox analysis revealed that post-treatment CALLY values were significantly associated with OS, LPFS, and DMFS. Patients with lower post-treatment CALLY values exhibited poorer survival outcomes compared with those with higher CALLY values.

conclusionsThese findings demonstrate that the post-treatment CALLY index could be a valuable tool for predicting prognosis and guiding subsequent treatment strategies in patients with LA-NSCLC undergoing thoracic RT. Further prospective studies are warranted to validate these results and to explore the potential of incorporating the CALLY index into clinical decision-making.

Indexed as

Carcinoma, Non-Small-Cell LungC-Reactive ProteinLung NeoplasmsAdultAgedAged, 80 and overBiomarkers, TumorFemaleHumansKaplan-Meier EstimateLymphocyte CountMaleMiddle AgedPrognosisRetrospective StudiesBiomarkers, TumorC-Reactive ProteinC-reactive protein–albumin–lymphocyte (CALLY) indexGross tumor volume (GTV)Locally advanced non-small cell lung cancer (LA-NSCLC)Radiotherapy(RT)

Identifiers

PMID42032543
PMCPMC13244888

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.